JOP20200053A1 - تركيبات كوبانليسيب - Google Patents

تركيبات كوبانليسيب

Info

Publication number
JOP20200053A1
JOP20200053A1 JOP/2020/0053A JOP20200053A JOP20200053A1 JO P20200053 A1 JOP20200053 A1 JO P20200053A1 JO P20200053 A JOP20200053 A JO P20200053A JO P20200053 A1 JOP20200053 A1 JO P20200053A1
Authority
JO
Jordan
Prior art keywords
copanlisib
stable
bulk solution
lyophilisation
increased solubility
Prior art date
Application number
JOP/2020/0053A
Other languages
English (en)
Inventor
Freundlieb Julia
Jacobs Tia
Original Assignee
Bayer Consumer Care AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17207771.1A external-priority patent/EP3498266A1/en
Application filed by Bayer Consumer Care AG, Bayer Pharma AG filed Critical Bayer Consumer Care AG
Publication of JOP20200053A1 publication Critical patent/JOP20200053A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Road Signs Or Road Markings (AREA)
  • Luminescent Compositions (AREA)

Abstract

الملخص يتعلق الاختراع الحالي بـ: • طريقة لتحضير محلول حجمي محتوي على الكوبانليسيب مائي ملائم للتجفيد وللتطبيقات العلاجية؛ • محلول حجمي محتوي على الكوبانليسيب، مستقر، ذو ذائبية مرتفعة ملائم للاستخدام مباشرةً في التجفيد؛ • طريقة لتجفيد المحلول الحجمي المائي المحتوي على الكوبانليسيب المذكور؛ • مادة صلبة محتوية على الكوبانليسيب مجفدة ومستقرة، وبالتحديد مسحوق أو كتلة، وتحديداً محتوية على جرعة علاجية من الكوبانليسيب في عبوة واحدة أو اثنتين، وبالتحديد عبوة محكمة الإغلاق واحدة، • طريقة لإعادة تكوين نواتج التجفيد هذه؛ و • محلول محتوي على الكوبانليسيب، معاد تكوينه ومستقر ذو ذائبية مرتفعة، ملائم لخطوة تخفيف إضافية وللتطبيقات العلاجية.
JOP/2020/0053A 2017-09-08 2018-09-06 تركيبات كوبانليسيب JOP20200053A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190117 2017-09-08
EP17207771.1A EP3498266A1 (en) 2017-12-15 2017-12-15 Formulations of copanlisib
PCT/EP2018/073965 WO2019048527A1 (en) 2017-09-08 2018-09-06 COPANLISIB FORMULATIONS

Publications (1)

Publication Number Publication Date
JOP20200053A1 true JOP20200053A1 (ar) 2020-03-08

Family

ID=63407234

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0053A JOP20200053A1 (ar) 2017-09-08 2018-09-06 تركيبات كوبانليسيب

Country Status (35)

Country Link
US (1) US20200281932A1 (ar)
EP (1) EP3678644B1 (ar)
JP (2) JP2020533292A (ar)
KR (1) KR20200052326A (ar)
CN (1) CN111278430A (ar)
AU (1) AU2018328812A1 (ar)
BR (1) BR112020004545A2 (ar)
CA (1) CA3074890A1 (ar)
CL (1) CL2020000584A1 (ar)
CO (1) CO2020002628A2 (ar)
CR (1) CR20200111A (ar)
CU (1) CU24607B1 (ar)
DK (1) DK3678644T3 (ar)
DO (1) DOP2020000054A (ar)
ES (1) ES2950663T3 (ar)
FI (1) FI3678644T3 (ar)
GE (1) GEP20237486B (ar)
HR (1) HRP20230612T1 (ar)
HU (1) HUE063178T2 (ar)
IL (1) IL272857B2 (ar)
JO (1) JOP20200053A1 (ar)
LT (1) LT3678644T (ar)
MA (1) MA50068A (ar)
MX (1) MX2020002633A (ar)
NI (1) NI202000019A (ar)
PH (1) PH12020500448A1 (ar)
PL (1) PL3678644T3 (ar)
RS (1) RS64316B1 (ar)
SG (1) SG11202001696QA (ar)
SI (1) SI3678644T1 (ar)
TW (1) TWI794288B (ar)
UA (1) UA126817C2 (ar)
UY (1) UY37868A (ar)
WO (1) WO2019048527A1 (ar)
ZA (1) ZA202002378B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4070785B1 (en) 2021-04-06 2023-11-08 Synthon B.V. Lyophilized composition of copanlisib salt
CN115252613B (zh) * 2022-08-09 2024-01-12 北京清华长庚医院 药物组合物及其在逆转仑伐替尼耐药性中的用途
WO2024069239A1 (en) * 2022-09-28 2024-04-04 Urogen Pharma Ltd. Compositions comprising a thermoreversible hydrogel, and having an extended in-use period

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312843T3 (es) 2002-09-30 2009-03-01 Bayer Healthcare Ag Derivados de azolpirimidina condensados.
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
AU2017214230A1 (en) * 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
WO2017134030A1 (en) * 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers

Also Published As

Publication number Publication date
CN111278430A (zh) 2020-06-12
MX2020002633A (es) 2020-07-13
RS64316B1 (sr) 2023-08-31
PL3678644T3 (pl) 2023-09-11
CU20200017A7 (es) 2020-11-30
GEP20237486B (en) 2023-03-27
CU24607B1 (es) 2022-06-06
CR20200111A (es) 2020-07-24
CO2020002628A2 (es) 2020-04-01
SG11202001696QA (en) 2020-03-30
SI3678644T1 (sl) 2023-08-31
NI202000019A (es) 2020-08-28
JP2023071917A (ja) 2023-05-23
IL272857B2 (en) 2024-03-01
UY37868A (es) 2019-04-30
CL2020000584A1 (es) 2020-08-21
HRP20230612T1 (hr) 2023-09-29
AU2018328812A1 (en) 2020-03-12
DK3678644T3 (da) 2023-07-31
DOP2020000054A (es) 2020-09-30
MA50068A (fr) 2021-06-02
PH12020500448A1 (en) 2021-02-08
TWI794288B (zh) 2023-03-01
FI3678644T3 (fi) 2023-07-28
KR20200052326A (ko) 2020-05-14
UA126817C2 (uk) 2023-02-08
IL272857B1 (en) 2023-11-01
CA3074890A1 (en) 2019-03-14
LT3678644T (lt) 2023-06-26
JP2020533292A (ja) 2020-11-19
TW201919636A (zh) 2019-06-01
ZA202002378B (en) 2023-10-25
EP3678644B1 (en) 2023-05-03
IL272857A (en) 2020-04-30
BR112020004545A2 (pt) 2020-09-08
US20200281932A1 (en) 2020-09-10
ES2950663T3 (es) 2023-10-11
EP3678644A1 (en) 2020-07-15
WO2019048527A1 (en) 2019-03-14
HUE063178T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
ZA202002378B (en) Formulations of copanlisib
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
MY189551A (en) Formulation of a peptide vaccine
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
NZ728401A (en) High purity oritavancin and method of producing same
MX2020002896A (es) Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica.
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
MX2017004764A (es) Formulacion de polvo seco.
PH12016501877A1 (en) Lypophilized factor ix formulations
IN2014DN09993A (ar)
EA202090568A1 (ru) Составы копанлисиба
GB201122430D0 (en) Reconstitution method for high concentration dry protein formulation
IL262494A (en) A pharmaceutical combination preparation containing Ivacaptor and Lomaceptor complex compositions, their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
AR112753A1 (es) Formulaciones de copanlisib
MX2019013053A (es) Composicion que contiene ciclodextrina y busulfan.
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
MX2015009141A (es) Formulaciones de albu-bche, preparacion y usos de las mismas.
GR1008818B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
MX2017012633A (es) Proceso para la fabricación de mezclas de polvo seco.
IN2014MU01178A (ar)